Elixiron Immunotherapeutics Inc.

Elixiron Immunotherapeutics is a clinical-stage biotech company committed to developing precision immunotherapies for neuroinflammatory and autoimmune diseases. Backed by decades of expertise in immunology and drug development, Elixiron has advanced two promising candidates into clinical trials: Enrupatinib for Alzheimer’s disease and Indemakitug for vitiligo. The company is a two-time recipient of the Alzheimer’s Association Part the Cloud award and has secured two out-licensing agreements.
Microglia-mediated neuroinflammation is a key driver of neurodegeneration and neuronal dysfunction in diseases such as Alzheimer’s, Parkinson’s disease and amyotrophic lateral sclerosis. As a result, targeting microglia and neuroinflammation has emerged as a major strategy for disease-modifying therapies. Elixiron’s lead candidate, Enrupatinib, is an award-winning, microglia-targeting immunotherapy currently in a Phase II clinical trial for Alzheimer’s disease. It acts by selectively inhibiting the colony stimulating factor 1 receptor (CSF-1R) on brain microglia, potentially reducing neuroinflammation and preserving cognitive function—an effect supported by animal models of Alzheimer’s disease.